Document Detail

Management of pulmonary embolism: state of the art treatment and emerging research.
MedLine Citation:
PMID:  23378176     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Pulmonary embolism is one of the most important causes of morbidity and mortality in cardiovascular medicine and demands a circumscribed algorithmic treatment approach (Fig. 1). Anticoagulation should be triggered by a high clinical probability and continued based on urgent definitive imaging. Our assessment then continues with evaluation of the clinical severity of the pulmonary embolism to determine whether the patient will benefit from thrombolysis or not. We usually reserve this option for cases of massive pulmonary embolism (sustained hypotension, pulselessness, or persistent profound bradycardia) or patients with a low cardiopulmonary reserve and categorical signs of right ventricle failure. At this juncture, renal function, a diagnosis of active cancer, calculated bleeding risk, and estimated patient compliance will help us gravitate toward specific agent selection for subsequent anticoagulation management. While rivaroxaban is an attractive oral therapy option, it is not an appropriate choice for patients with significant renal disease; patients with cancer are better treated with low molecular weight heparin when possible. Warfarin anticoagulation continues to be a well-known, valid, and cost-effective treatment option. At the end of the primary treatment we assess each patient for the likelihood of thromboembolism recurrence, which will be highest among those patients with idiopathic events or those with cancer-associated thrombosis. We favor prolonged anticoagulation in these scenarios. In addition, we strongly advocate periodic scheduled follow up of patients on long-term anticoagulation for secondary prophylaxis to re-evaluate their bleeding and recurrence risk. We understand both of these extremes are in a dynamic balance, and likewise so should be the anticoagulation directives. As we learn more about recurrence and bleeding prediction, we foresee a personalized approach in which the anticoagulant agent for each patient will be narrowly chosen based on their specific performance.
Omar Esponda; Alfonso Tafur
Related Documents :
16549746 - Recovery of olfactory function following closed head injury or infections of the upper ...
21090556 - The prognostic significance of thoracic and abdominal trauma in severe trauma patients ...
3175836 - Head trauma and nonsurvival--a sample survey.
10091496 - Disturbances in plasma sodium in patients with war head injuries.
22261626 - A comparison of acute kidney injury classifications in patients with severe sepsis and ...
7575256 - Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratiti...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current treatment options in cardiovascular medicine     Volume:  15     ISSN:  1092-8464     ISO Abbreviation:  Curr Treat Options Cardiovasc Med     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-27     Completed Date:  2013-03-28     Revised Date:  2013-07-25    
Medline Journal Info:
Nlm Unique ID:  9815942     Medline TA:  Curr Treat Options Cardiovasc Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  137-52     Citation Subset:  -    
Cardiovascular Medicine -Vascular Medicine, Oklahoma University Health and Sciences Center, 920 Stanton L Young Blvd. WP 3010, Oklahoma City, OK, 73104, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prediction of body weight from body measurements in grass cutters.
Next Document:  Organic-inorganic hybrid fluorous monolithic capillary column for selective solid-phase microextract...